By boosting innate immunity, researchers eradicate aggressive prostate cancer in mice March 8, 2017 Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.Read more.Source: Medical Xpress About Prostate Cancer Advanced Prostate Cancer Clinical Trials Prostate Cancer News More for you
Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.Read more.Source: Medical Xpress
